Discover
XLO
Xilio Therapeutics, Inc.
9.22
2 x 6.72
2 x 11.78
bid
ask
-
0.36
3.76%
2 @ 04:00 PM
9.05 -0.17 (1.84%)
| Ytd | 2.90% | |
| 1y | -4.95% |
9.05
day range
9.60
6.47
52 week range
12.74
| Open | 9.45 | Prev Close | 9.58 | Low | 9.05 | High | 9.60 | Mkt Cap | 60.62M |
| Vol | 21.75K | Avg Vol | 43.87K | EPS | -2.28 | P/E | N/A | Forward P/E | -1.91 |
| Beta | -0.20 | Short Ratio | 0.42 | Inst. Own | 29.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.33 | 200-d Avg | 9.15 | 1yr Est | 4.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.25 | -0.22 | 0.03 | 12.00% |
| 2024-08-08 | 2024-06 | -0.23 | N/A | N/A | N/A |
| 2024-08-08 | 2024-06 | -0.23 | -0.24 | -0.01 | -4.35% |
| 2024-05-14 | 2024-03 | -0.3 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -0.3 | -0.59 | -0.29 | -96.67% |
| 2024-04-01 | 2023-12 | -0.62 | -0.64 | -0.02 | -3.23% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-08 | Raymond James | Upgrade | Outperform | Outperform |
| 2023-05-30 | Chardan Capital | Upgrade | Buy | Buy |
| 2023-05-11 | Chardan Capital | Upgrade | Buy | |
| 2023-01-27 | Morgan Stanley | Upgrade | Overweight | |
| 2022-12-21 | Chardan Capital | Upgrade | Buy | |
| 2022-11-10 | Raymond James | Upgrade | Outperform |
Profile
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-02-07 | ATLAS VENTURE FUND XI L.P | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2024-12-17 | GILEAD SCIENCES INC | Beneficial Owner of more than 10% of a Class of Security | 9.11M | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Bain Capital Life Sciences Investors, LLC | 4.57M | 5.07M | 10.39% |
| 2024-09-29 | Rock Springs Capital Management, LP | 3.00M | 3.33M | 6.83% |
| 2024-09-29 | Morgan Stanley | 1.52M | 1.69M | 3.46% |
| 2024-09-29 | Rivervest Venture Management LLC | 1.44M | 1.60M | 3.28% |
| 2024-09-29 | FMR, LLC | 1.40M | 1.55M | 3.18% |
| 2024-09-29 | Vanguard Group Inc | 902.53K | 1.00M | 2.05% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 739.56K | 820.91K | 1.68% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 182.83K | 202.94K | 0.42% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 160.02K | 177.63K | 0.36% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 71.08K | 78.90K | 0.16% |
| 2024-10-30 | Fidelity Total Market Index Fund | 63.99K | 71.03K | 0.15% |
| 2024-10-30 | iShares Micro Cap ETF | 66.92K | 74.28K | 0.15% |
Split
| Split | Date |
|---|---|
| 1 : 14 | 2026-03-16 |